Cannabinoids can activate CB 1 and CB 2 receptors. Since a CB 2 mRNA has been described in rat peritoneal mast cells (RPMC), we investigated a series of cannabinoids and derivatives for their capacity to stimulate RPMC. Effects of natural cannabinoids v 9 -tetrahydrocannabinol (v 9 -THC), v 8 -THC, endocannabinoids (anandamide, palmitoylethanolamide) and related compounds (N-decanoyl-, N-lauroyl-, N-myristoyl-, N-stearoyl-and N-oleoyl-ethanolamines ; N-palmitoyl derivatives (-butylamine, -cyclohexylamine, -isopropylamine) ; and N-palmitoyl, O-palmitoylethanolamine), and synthetic cannabinoids including WIN 55,212-2, SR141716A and SR144528 were assessed for their capacity to induce histamine release or prime RPMC stimulated by compound 48/80. Only v 9 -THC and v 8 -THC could induce non-lytic, energy-and concentration-dependent histamine releases from RPMC (respective EC 50 values: 23.5 þ 1.2; 53.4 þ 20.6 WM, and maxima : 71.2 þ 5.5; 55.7 þ 2.7% of the total RPMC histamine content). These were not blocked by CB 1 (SR141716A) or CB 2 (SR144528) antagonists, but reduced by pertussis toxin (100 ng/ml). Endocannabinoids and analogues did neither induce histamine secretion, nor prime secretion induced by compound 48/80 (0.2 Wg/ml). v 9 -THC and v 8 -THC induced in vitro histamine secretion from RPMC through CB receptor-independent interactions, partly involving G iao protein activation. ß
Introduction
Mast cells and basophils are polyfunctional immune cells implicated in immediate hypersensitivity and the initiation and development of the in£amma-tory reaction. These cells are present in many tissues and their activation results in the release of potent preformed and newly formed mediators, such as histamine, proteases, cytokines or metabolites of arachidonic acid. The direct consequence of this activation is tissue swelling and/or damage, modi¢cation of function, leucocyte invasion and pain. Abnormal regulation of mast cell physiology leading to cell secretion may represent a pathophysiological situation leading to chronic in£ammation and ultimately to a loss of tissue and/or organ function [1] .
Natural cannabinoids, originally extracted from the leaves of Cannabis sativa, were used for over 4000 years both for their medicinal and psychomimetic e¡ects. v 9 -Tetrahydrocannabinol (v 9 -THC) was the ¢rst active isolated cannabinoid, or marihuana-derived molecule, and was described as highly psychoactive [2] . Recently discovered and cloned receptors [3^5] for cannabinoids have speeded up the understanding of their underlying molecular mechanisms. The two subtypes of these G protein coupled receptors are the CB 1 , very abundant in the brain areas and supposed to mediate neurobehavioural e¡ects, and the CB 2 , restricted to date on cells of the immune system, and thought to modulate immunological responses.
A potential endogenous lipidic ligand was ¢rst discovered in porcine brain [6] and shown to have functional e¡ects in vitro or in vivo in the rat brain [7, 8] . This molecule, N-arachidonoylethanolamine or anandamide, was also shown to have functional activity in mouse vas deferens [6] and its presence was noticed in peripheral tissues of rat and human beings [9] . The central/peripheral classi¢cation may therefore be too elementary. Another endogenous compound, N-palmitoylethanolamine (PEA), ¢rst described to be present in the rat brain, liver and muscle [10] , was reported to be a potent nanomolar agonist for the CB 2 receptor [11] and to display antiin£ammatory e¡ects [12, 13] . The absence of binding of this compound to brain membranes suggested a high selectivity for peripheral CB 2 receptor [14, 15] . However, several authors failed to ¢nd any PEA binding to CB 2 receptors ( [16] for review). PEA, as other N-acylated glycerophospholipids, has been shown to accumulate in in£ammatory tissues [17] . It reduces tissue in£ammation in vivo [18] , downmodulates mast cell activation in vivo [19] and in contrast to anandamide, inhibits immunogenic activation in RBL-2H3 cells [11] . The capacity of these plant-derived or endogenous molecules to modify mast cell histamine release in vitro is currently unknown. To address this question, we assessed for this function cannabinoids from natural (v 9 -and v 8 -THC), endogenous (anandamide and PEA) and synthetic (palmitoylethanolamide analogues, WIN 55,212-2, SR141716A and SR144528) origin. Considering the di¡erent pathways of activation of rat peritoneal mast cells (RPMC) and the existence of a modulation by PEA of the immunological one [11] , we focused our interest on the e¡ect of these various cannabinoids on the secretion occurring through the alternate, receptor-independent pathway of mast cell stimulation [20^22].
Materials and methods

Chemistry
N-Acylethanolamines including PEA (Table 1 , compounds 1^10) were prepared as described elsewhere [23] , from their respective acyl chlorides and amines. Spectroscopic data ( 1 H-and 13 C-nuclear magnetic resonance, IR) and elemental analysis were in accordance with their chemical structures. 
Chemicals
Mast cells
The procedure followed in the care and euthanasia of the animals was in accordance with the European Community standards on the care and use of laboratory animals (Europe Directive 86/609/CEE Nov. 24, 86). RPMC were puri¢ed from male albino Wistar rats weighing 300^350 g. The rats were sacri¢ced by stunning and bleeding. Then, 10 ml of physiological salt solution (PSS) containing (mM): NaCl, 137; KCl, 2.7; CaCl 2 , 0.3; MgCl 2 , 1; NaH 2 PO 4 , 0.4; glucose, 5.6; HEPES [4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid], 10 and NaOH to pH 7.4, sup-plemented with 0.2% BSA, were injected intraperitoneally. The peritoneal cavity was opened after a 2 min gentle massage and the peritoneal £uid collected and centrifuged for 2 min at 180Ug. Mast cells were puri¢ed from the resuspended pellet by centrifugation for 10 min at 220Ug on a BSA gradient (40 and 30%, w/v). 
Histamine release from mast cells
After a 5 min equilibration period of the mast cells (15 000^20 000 puri¢ed mast cells/assay) at 37³C in PSS, the cells were challenged for 5 min with the various compounds. The reactions were stopped by adding ice cold bu¡er to the samples. Histamine from supernatants was assayed £uorometrically according to the method of Shore et al. [24] without extraction steps, and expressed as a percentage of the total histamine content of the cells, determined by lysing control cells with trichloroacetic acid. Spontaneous histamine release never exceeded 8% and was subtracted from the induced releases.
Inhibition of histamine release
Treatment of the mast cells with 5.6 mM 2-deoxy-D-glucose (instead of 5.6 mM glucose, control) and/ or 100 WM dinitrophenol was done in PSS for 30 min at 37³C. The e¡ect of pertussis toxin on histamine release was assessed after incubation of the mast cells for 2 h at 37³C in PSS. After either of these treatments, the cells were challenged for 5 min with the various cannabinoids as described above.
The e¡ect of BAC, a mixture of quaternary benzyldimethylalkylammonium chlorides, on histamine release was assayed as described previously [25] , allowing BAC and the cannabinoids to act simultaneously for 10 min at 37³C on puri¢ed mast cells in PSS.
Statistics
Values are means þ S.E.M. of the indicated number of duplicate experiments. Statistical analyses of data were established using the two-tail Student's t-test (*P 6 0.05, signi¢cantly di¡erent from control).
Results
E¡ects of natural and synthetic cannabinoids on histamine release from mast cells
Natural cannabinoids v 9 -THC or v 8 -THC, endogenous molecules anandamide or PEA, PEA derivatives (Table 1, antagonists, respectively) or WIN 55,212-2 were assayed as triggers for histamine release from rat peritoneal mast cells. Fig. 1 shows that only v 9 -THC and v 8 -THC were able to induce a concentration-dependent histamine release, with EC 50 values of 23.5 þ 1.2 and 53.4 þ 20.6 WM, reaching a maximum of 71.2 þ 5.5 and 55.7 þ 2.7% of the total histamine content of the cells, respectively. Anandamide had no e¡ect on histamine release until 3U10
34 M (Fig. 1) .
Metabolic dependence of cannabinoid-induced histamine release
Due to the high cannabinoid concentrations needed to induce histamine liberation, experiments were carried out with 2-deoxy-D-glucose (non-hydrolysable glucose substitute) and/or DNP (mitochondrial respiration chain blocker) to assess the functionality of the histamine secretion from mast cells and to verify that histamine was not released through membrane destruction. Inhibition of the histamine release induced by v 9 -THC and v 8 -THC was partial by substituting glucose by 2-deoxy-D-glucose, but total when combined with DNP (Fig. 2) , showing the energy dependence, i.e. the physiological process of the mechanism. However, 2-deoxy-D-glucose and/or DNP did not inhibit the histamine release induced by the endogenous cannabinoid anandamide (Fig. 2) , suggesting a non-physiological, possibly deleterious e¡ect on mast cell membranes.
Receptor-independent e¡ects of cannabinoids in rat mast cells
The CB antagonists SR141716A and SR144528, assayed up to 10 WM on histamine secretion induced by v 9 -THC (Fig. 3A) and v 8 -THC (Fig. 3B) , only showed signi¢cant inhibitory e¡ects when used at the highest concentration and for only one concentration (3U10 35 M) of both cannabinoids. PTX was able to inhibit histamine secretion by up to 75% in the case of v 8 -THC (Fig. 4) , the histamine Table 1 Homologues (1^6) and analogues (7^10) of N-palmitoylethanolamine releaser compound 48/80 being used as internal control. On the other hand, up to its subtoxic concentrations, BAC, supposed to interact with G-proteins, showed no e¡ect on histamine secretion induced by the natural cannabinoids (Fig. 5) . All PEA derivatives were also assayed as potential primers for the histamine secretion induced by compound 48/80 to highlight a possible modulatory e¡ect (Table 2) . For all the derivatives and concentrations tested, only Npalmitoylcyclohexylamine (8) showed a signi¢cant inhibition (P 6 0.05), at 10 34 M, of the histamine secretion induced by compound 48/80.
[ 3 H]WIN 55,212-2 binding to mast cells
In our experimental conditions with intact RPMC, no speci¢c binding of a radioligand known to bind to both cannabinoid receptors with a preference for CB 2 , was observed.
Discussion
Mast cells are polyfunctional immune cells implicated in allergy and in the development of in£amma-tion. As a CB 2 mRNA has been described in mast cells [11] , they may represent a potential target for cannabinoids. Cannabinoid receptors recognized a diversity of chemical structures. In this investigation of the e¡ects of cannabinoids to induce or modulate histamine release from rat peritoneal mast cells, we include di¡erent cannabinoids di¡ering by their source (natural, endogenous, synthetic) and by their function (agonists, antagonists). We show that rat peritoneal mast cells are able to secrete histamine when stimulated by v 9 -and v 8 -THC, two wellknown potent natural cannabinoids [26] . This e¡ect is not shared by other cannabinoids used in this study, whatever their function on the receptors: both agonists (WIN 55,212-2) and antagonists (SR141716A and SR144528) as well as analogues of palmitoylethanolamide have no e¡ect on histamine release. The only exception was anandamide. However, this could only be observed at a high concentration, which proved to be deleterious to mast cells, as energy deprivation did not lower anandamide-induced histamine release. Obviously, the ability to modulate histamine secretion strictly depends on the chemical structure: only the cannabinoids containing the benzopyran ring exhibited these properties.
PEA has been reported to be highly e¡ective in reducing antigen-evoked [ 3 H]serotonin release from RPMC [11] . It can moderate mast cell activation induced in vivo by substance P, which would point towards a local autacoid anti-in£ammatory function [19] . Substance P triggers rat peritoneal mast cells through a non-immunological transductional pathway, often referred to as peptidergic pathway and common to amphiphilic positively charged molecules (e.g. compound 48/80 or mastoparan [20, 21, 27, 28] [5, 29] , and the presence of CB 2 mRNA has previously been noticed in rat peritoneal mast cells [11] . However, we did not observe CB 2 receptors in RPMC with [ 3 H]WIN 55,212-2, a preferential CB 2 ligand [30] . Also, SR144528, a CB 2 antagonist [31] , did not reduce histamine release induced by v 9 -or v 8 -THC. As these are known to be active on both CB 1 and CB 2 receptors, we used the CB 1 antagonist SR141716A [32] to evidence a possible CB 1 receptor-mediated subtype on mast cells. SR141716A did not reduce histamine release induced by v 9 -or v 8 -THC, suggesting that no CB 1 receptors are involved in this mechanism. Therefore, our results do not support the hypothesis of the presence of functional CB 1 or CB 2 receptors in rat peritoneal mast cells in our experimental conditions. PTX-sensitive G i and G o proteins have been found in RPMC [20, 22, 28, 33] and are implicated in the peptidergic receptor-independent stimulation pathway. Benzalkonium chloride, a germicide shown to be a selective inhibitor of histamine release induced by compound 48/80 [25] and supposed to act at the Gprotein level, revealed no signi¢cant concentrationdependent inhibitory e¡ect on histamine release induced by v 9 -THC or v 8 -THC. However, PTX partially reduced histamine secretion induced by v 9 -and v 8 -THC, indicating that G iao proteins were only partly responsible for this phenomenon. CB 1 and CB 2 receptors have been shown to couple to PTXsensitive G-proteins [34, 35] , but our results in RPMC do not support a classical ligand-receptor interaction. Instead, we wish to propose that v 9 -and v 8 -THC are capable of inducing histamine release by using, only to a certain extent, the peptidergic G iao -related secretion pathway.
Natural cannabinoids may exert immunosuppressive e¡ects, at high concentrations, by inhibiting the B lymphocyte proliferation [36, 37] . This e¡ect was not blocked by pertussis toxin pretreatment, indicating the involvement of cannabinoid-induced membrane e¡ects on lymphocytes [38] in addition to their low nanomolar immunostimulant receptor-mediated e¡ects [38] . Cannabinoids can indeed a¡ect enzymes or ion channels [39^43]. Membrane structure seems to be modi¢ed by cannabinoids: they can position themselves within or near the membrane [44, 45] , or change lipid order [46] and di¡usion [47^49] . Some e¡ects were also found not to be correlated with pharmacological potency [46] . Considering (i) the particularity of RPMC, which can secrete histamine following the classical immunological or the peptidergic receptor-independent activation, and (ii) the highly hydrophobic structure of v 9 -THC, v 8 -THC, PEA and the other cannabinoids described above, it may be assumed that all the effects observed in these cells may result from CB receptor-independent interactions. These interactions, deleterious in the case of anandamide, remain physiological even at high concentrations for the two active molecules, the plant-derived v 9 -THC and v 8 -THC. Moreover, they partly involve G iao protein activation.
